{"createdAt":"8/2/2020, 2:34:58 PM","timestamp":1596393298777,"Company ID number":"626","DMX_ISSUER_NAME":"Humanwell Healthcare (Group) Co., Ltd.","DMX_ISSUER_ID":"IID000000002189822","Country of Classification":"CHINA","name":"Humanwell Healthcare Group Co Ltd ","code":"600079","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"人福医药集团股份公司_李杰","group":"board","name":"李杰","title":"董事长,董事","isMale":true,"age":"65","degree":"本科","salary":"80.00万","stockAmount":"614.4万","description":"李杰,男,1955年7月生,中国国籍,中共党员,大学本科,正高级工程师,2003年5月至今任人福医药集团股份公司董事,2006年9月至2020年4月任公司总裁,2020年4月至今任人福医药集团股份公司董事长。","lastUpdated":"2020-06-02"},{"id":"人福医药集团股份公司_邓霞飞","group":"board","name":"邓霞飞","title":"董事","isMale":true,"age":"57","degree":"博士","salary":"75.60万","stockAmount":"73.7万","description":"邓霞飞,男,1963年12月生,中国国籍,农工党员,工学博士,正高级工程师,1998年3月至2020年4月任公司副总裁,2000年8月至今任人福医药集团股份公司董事,2020年4月至今任人福医药集团股份公司总裁。","lastUpdated":"2020-06-02"},{"id":"人福医药集团股份公司_张小东","group":"board","name":"张小东","title":"董事","isMale":true,"age":"69","degree":"硕士","salary":"80.00万","stockAmount":"46.03万","description":"张小东,男,1951年9月生,中国国籍,中共党员,硕士,正高级经济师,现任当代科技董事、武汉当代科技投资有限公司董事兼总经理、武汉当代乾源科技有限公司董事、武汉明诚金石科技有限公司董事、天风证券董事、广州卓润机电设备有限公司执行董事及总经理等,1997年1月至今任人福医药集团股份公司董事。","lastUpdated":"2020-05-30"},{"id":"人福医药集团股份公司_周汉生","group":"board","name":"周汉生","title":"董事","isMale":true,"age":"57","degree":"博士","salary":"0.00","stockAmount":"-","description":"周汉生,男,1963年6月生,中国国籍,民建会员,应用化学博士,现任当代科技董事长兼总经理、武汉当代科技投资有限公司董事长、武汉当代乾源科技有限公司董事长兼总经理、武汉明诚金石科技有限公司董事长兼总经理、华泰保险集团股份有限公司董事、武汉世众联教育投资有限公司董事、武汉上品书意文化有限公司执行董事及总经理等,2017年4月至今任人福医药集团股份公司董事。","lastUpdated":"2020-05-30"},{"id":"人福医药集团股份公司_王学海","group":"board","name":"王学海","title":"董事","isMale":true,"age":"46","degree":"博士","salary":"100.0万","stockAmount":"782万","description":"王学海,男,1974年8月生,中国国籍,中共党员,企业管理博士,正高级经济师。现任当代科技董事、武汉当代科技投资有限公司监事、武汉当代乾源科技有限公司监事、武汉明诚金石科技有限公司董事、湖北省长江产业投资集团有限公司董事、湖北机场集团有限公司董事、湖北楚商之家投资有限公司董事长、北京雷石原点集团股份有限公司董事、瑞多仕(武汉)制药有限公司董事、Douyuinternationalholdingslimited董事等,2006年9月至2020年4月任公司董事长,2003年5月至今任人福医药集团股份公司董事。","lastUpdated":"2020-05-30"},{"id":"人福医药集团股份公司_黄峰","group":"board","name":"黄峰","title":"董事","isMale":true,"age":"51","degree":"硕士","salary":"0.00","stockAmount":"-","description":"黄峰,男,1969年12月生,中国国籍,中共党员,经济管理专业研究生,曾任武汉光谷建设投资有限公司总经理、党委副书记、董事长,2016年11月至今任武汉高科国有控股集团有限公司党委书记、董事长,2018年5月至今任人福医药集团股份公司董事。","lastUpdated":"2020-05-30"},{"id":"人福医药集团股份公司_王学恭","group":"board","name":"王学恭","title":"独立董事","isMale":true,"age":"48","degree":"硕士","salary":"4.800万","stockAmount":"-","description":"王学恭,男,1972年出生,中国国籍,无境外永久居留权,硕士。曾任华药集团公司技术员、办公室副主任、营销战略部部长、资本运营部部长,2010年2月至2014年1月任中国医药企业管理协会副秘书长,2014年1月至今,任中国医药企业管理协会副会长。现任人福医药集团股份公司独立董事。2017年5月起,任北京诚益通控制工程科技股份有限公司独立董事。","lastUpdated":"2020-05-30"},{"id":"人福医药集团股份公司_何其生","group":"board","name":"何其生","title":"独立董事","isMale":true,"age":"46","degree":"博士","salary":"4.800万","stockAmount":"-","description":"何其生,男,1974年4月生,中国国籍,中共党员,国际法博士,曾任武汉大学法学院教授,现任北京大学法学院教授,2016年4月至今任人福医药集团股份公司独立董事。","lastUpdated":"2020-05-30"},{"id":"人福医药集团股份公司_刘林青","group":"board","name":"刘林青","title":"独立董事","isMale":true,"age":"46","degree":"博士","salary":"--","stockAmount":"-","description":"刘林青,男,出生于1974年,中国国籍,无境外居留权,博士研究生学历,注册会计师,中共党员。现为武汉大学经济与管理学院教授,MBA案例开发中心主任,曾在人民出版社发表了产业国际竞争力的二维评价及演化研究-全球价值链背景下的思考等多篇著作。刘林青先生曾在奥特佳、人福医药担任过独立董事。","lastUpdated":"2020-05-30"},{"id":"人福医药集团股份公司_杜越新","group":"supervisoryCommittee","name":"杜越新","title":"监事长","isMale":true,"age":"62","degree":"硕士","salary":"6.600万","stockAmount":"-","description":"杜越新,男,1958年8月生,中国国籍,中共党员,世界经济学硕士,现任天风证券董事、嘉德投资控股有限公司董事长、北京沃德韦尔节能环保科技有限责任公司董事、中诚信投资集团有限公司董事、北京智象信息管理咨询有限公司董事、《管理现代化》杂志社社长、上海苏珞商务咨询有限公司执行董事兼总经理等,2005年3月至今任人福医药集团股份公司监事长。","lastUpdated":"2020-06-02"},{"id":"人福医药集团股份公司_齐民","group":"supervisoryCommittee","name":"齐民","title":"监事","isMale":true,"age":"70","degree":"博士","salary":"4.800万","stockAmount":"-","description":"齐民,男,1950年4月生,中国国籍,中共党员,经济学博士,高级经济师,2001年5月至2013年7月任武汉三特索道集团股份有限公司董事长、党委书记,现任庐山三叠泉缆车有限公司董事、中电光谷联合控股有限公司独立非执行董事,2014年5月至今任人福医药集团股份公司监事。","lastUpdated":"2020-05-30"},{"id":"人福医药集团股份公司_郑承刚","group":"supervisoryCommittee","name":"郑承刚","title":"监事","isMale":true,"age":"49","degree":"硕士","salary":"--","stockAmount":"-","description":"郑承刚,男,1971年6月出生,中国国籍,中共党员,研究生学历,高级工程师,曾任武汉人福药业有限责任公司生产部部长,2004年至今任湖北葛店人福药业有限责任公司总经理、董事。","lastUpdated":"2020-05-30"},{"id":"人福医药集团股份公司_孔娜","group":"supervisoryCommittee","name":"孔娜","title":"职工监事","isMale":false,"age":"40","degree":"硕士","salary":"--","stockAmount":"-","description":"孔娜,女,1980年12月生,中国国籍、中共党员,经济管理专业在职研究生,曾任武汉市社会保险基金结算中心武汉养老保险科副科长、武汉当代科技产业集团股份有限公司人力资源部部长,2020年4月至今任人福医药集团股份公司党委副书记。","lastUpdated":"2020-04-30"},{"id":"人福医药集团股份公司_夏渊","group":"supervisoryCommittee","name":"夏渊","title":"职工监事","isMale":true,"age":"39","degree":"硕士","salary":"--","stockAmount":"-","description":"夏渊,男,1981年7月出生,中国国籍,经济法硕士,曾任汇康生物科技有限责任公司副总经理,2017年5月至今任人福医药集团股份公司行政总监。","lastUpdated":"2020-04-30"},{"id":"人福医药集团股份公司_邓霞飞","group":"manager","name":"邓霞飞","title":"总裁","isMale":true,"age":"57","degree":"博士","salary":"75.60万","stockAmount":"73.7万","description":"邓霞飞,男,1963年12月生,中国国籍,农工党员,工学博士,正高级工程师,1998年3月至2020年4月任公司副总裁,2000年8月至今任人福医药集团股份公司董事,2020年4月至今任人福医药集团股份公司总裁。","lastUpdated":"2020-06-02"},{"id":"人福医药集团股份公司_李前伦","group":"manager","name":"李前伦","title":"董事会秘书,副总裁","isMale":true,"age":"41","degree":"博士","salary":"45.00万","stockAmount":"-","description":"李前伦,男,1979年10月生,中国国籍,中共党员,法学博士,曾任天风证券财务顾问部总经理、武汉光谷创投基金管理有限公司总经理,2013年5月至今任人福医药集团股份公司副总裁、董事会秘书。","lastUpdated":"2020-06-02"},{"id":"人福医药集团股份公司_吴亚君","group":"manager","name":"吴亚君","title":"副总裁,财务总监","isMale":false,"age":"50","degree":"硕士","salary":"53.00万","stockAmount":"50.7万","description":"吴亚君,女,1970年5月生,中国国籍,高级会计师,武汉大学EMBA,2004年3月至今任人福医药集团股份公司副总裁、财务总监。","lastUpdated":"2020-06-02"},{"id":"人福医药集团股份公司_徐华斌","group":"manager","name":"徐华斌","title":"副总裁","isMale":true,"age":"62","degree":"本科","salary":"67.00万","stockAmount":"67.5万","description":"徐华斌,男,1958年11月生,中国国籍,中共党员,大学学历,正高级工程师,曾任宜昌人福药业有限责任公司副总裁,2003年2月至今任人福医药集团股份公司副总裁,2010年7月至今任宜昌人福药业有限责任公司董事。","lastUpdated":"2020-06-02"},{"id":"人福医药集团股份公司_杜文涛","group":"manager","name":"杜文涛","title":"副总裁","isMale":true,"age":"53","degree":"硕士","salary":"65.00万","stockAmount":"44.6万","description":"杜文涛,男,1967年2月生,中国国籍,中共党员,中南财经政法大学MBA、美国中康州大学EMBA,正高级工程师,2003年10月至今任人福医药集团股份公司副总裁,2014年4月至今任宜昌人福药业有限责任公司总裁、董事。","lastUpdated":"2020-06-02"},{"id":"人福医药集团股份公司_李莉娥","group":"manager","name":"李莉娥","title":"副总裁","isMale":false,"age":"55","degree":"硕士","salary":"--","stockAmount":"-","description":"李莉娥,女,1965年3月生,中国国籍,中共党员,药物化学硕士,正高级工程师,2001年10月至今任宜昌人福药业有限责任公司总工程师,2008年11月至今任人福医药集团股份公司总工程师,2012年10月至今任宜昌人福药业有限责任公司副总裁,2020年4月至今任人福医药集团股份公司副总裁。","lastUpdated":"2020-06-02"},{"id":"人福医药集团股份公司_张红杰","group":"manager","name":"张红杰","title":"副总裁","isMale":true,"age":"54","degree":"本科","salary":"--","stockAmount":"-","description":"张红杰,男,1966年7月生,中国国籍,中共党员,大学学历,正高级经济师,2012年4月至今任湖北人福医药集团有限公司董事长兼总经理,2020年4月至今任人福医药集团股份公司副总裁。","lastUpdated":"2020-06-02"},{"id":"人福医药集团股份公司_尹强","group":"manager","name":"尹强","title":"副总裁","isMale":true,"age":"39","degree":"硕士","salary":"--","stockAmount":"-","description":"尹强,男,1981年8月生,中国国籍,中共党员,药学硕士,高级经济师,人福医药集团股份公司项目经理、行政总监、新疆维吾尔药业有限责任公司总经理,2016年9月至今任新疆维吾尔药业有限责任公司董事长,2020年4月至今任人福医药集团股份公司副总裁。","lastUpdated":"2020-06-02"}],"companyName":"人福医药集团股份公司","province":"湖北省","englishName":"Humanwell Healthcare Group Co Ltd","industry":"医药生物 — 化学制药","website":"www.humanwell.com.cn","mainBusiness":"医药产业产品的生产、研发和销售等。","productsName":["药品","医疗器械","安全套"],"actualController":"艾路明","actualControllerSharePercentage":"8.32%","registeredCapital":"13.54亿元","employeeAmount":"15711","phone":"86-027-87597232","location":"湖北省武汉市洪山区东湖高新区高新大道666号","chineseDescription":"人福医药集团股份公司是以房地产、生殖健康、医药为主要产业的集团公司。主要生产药品、安全套等为产品。\n　　公司坚持实施国际化战略，面向全球医药市场进行产业布局，海外业务现已覆盖了欧美成熟市场以及南美、东南亚、中亚、西非、东非等新兴市场。","foundedDate":"1993-03-30","goPublicDate":"1997-06-06","companyHistory":"","shareholders":[{"organizationId":"00205850","holderName":"武汉当代科技产业集团股份有限公司","totalShare":"3.96亿","sharePercentage":"29.26%"},{"organizationId":"","holderName":"上海高毅资产管理合伙企业(有限合伙)-高毅邻山1号远望基金","totalShare":"6500.00万","sharePercentage":"4.80%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"4259.23万","sharePercentage":"3.15%"},{"organizationId":"T000073058","holderName":"中国证券金融股份有限公司","totalShare":"4059.53万","sharePercentage":"3.00%"},{"organizationId":"","holderName":"全国社保基金一一三组合","totalShare":"3960.47万","sharePercentage":"2.93%"},{"organizationId":"00056872","holderName":"UBSAG","totalShare":"3434.70万","sharePercentage":"2.54%"},{"organizationId":"","holderName":"基本养老保险基金八零二组合","totalShare":"3025.33万","sharePercentage":"2.23%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"2854.52万","sharePercentage":"2.11%"},{"organizationId":"","holderName":"泰康人寿保险有限责任公司-传统-普通保险产品-019L-CT001沪","totalShare":"2284.77万","sharePercentage":"1.69%"},{"organizationId":"","holderName":"泰康人寿保险有限责任公司-分红-个人分红-019L-FH002沪","totalShare":"1563.14万","sharePercentage":"1.15%"}],"englishDescription":"Humanwell Healthcare (Group) Co., Ltd is a China-based company principally engaged in research and development, manufacture and distribution of medical and pharmaceutical products. The Company鈥檚 products are categorized into chemical drugs, chemical raw material medicines, traditional Chinese medicines, biological medicines and others. The Company also provides medical instruments. The Company distributes its products in both domestic market and to overseas markets.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"58.92","Price to sales (ttm)":"2.11","Price to book (mrq)":"4.40","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"149.37","Lt debt to equity (mrq)":"44.66","Return on investment (ttm)":"8.17","Return on equity (ttm)":"3.50","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"21,881.08","Cash payments":"(13,185.83)","Cash taxes paid":"(1,345.61)","Changes in working capital":"(5,311.81)","Cash from operating activities":"2,037.83","Capital expenditures":"(809.59)","Other investing cash flow items, total":"756.36","Cash from investing activities":"(53.23)","Financing cash flow items":"(2,278.15)","Total cash dividends paid":"(974.11)","Issuance (retirement) of debt, net":"388.94","Cash from financing activities":"(2,863.32)","Foreign exchange effects":"42.99","Net change in cash":"(835.73)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"32.92","52 Week High":"35.69","52 Week Low":"9.47","Pricing date":"","10 Day Average Trading Volume":"21.05","Market Capitalization":"44,563.95","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"450.20","Beta":"1.34","1 Day Price Change":"0.37","13 Week Price Return (Daily)":"59.03","26 Week Price Return (Daily)":"124.40","5 Day Price Return (Daily)":"4.14","52 Week Price Return (Daily)":"210.27","Year To Date Price Return (Daily)":"143.67","Month to Date Price Return (Daily)":"20.94","Price Relative to S&P500 (4 Week)":"22.30","Price Relative to S&P500 (13 Week)":"37.42","Price Relative to S&P500 (26 Week)":"101.80","Price Relative to S&P500 (52 Week)":"172.66","Price Relative to S&P500 (YTD)":"124.54"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.58","EPS excl. Extra Items (TTM)":"0.56","EPS Normalized (Annual)":"0.51","Revenue per Share (Annual)":"16.14","Revenue per Share (TTM)":"15.60","Book Value (Per Share Annual)":"7.50","Book Value (Per Share Quarterly)":"7.49","Tangible Book Value (Per Share Annual)":"2.58","Tangible Book Value (Per Share Quarterly)":"2.54","Cash Per Share (Per Share Annual)":"2.98","Cash Per Share (Per Share Quarterly)":"3.93","Cash Flow (Per Share Annual)":"1.43","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.05","Dividends (Per Share TTM)":"0.05","EBITD (Per Share TTM)":"1.75","EPS Basic excl. Extra Items (Annual)":"0.58","EPS Basic excl. Extra Items (TTM)":"0.56","EPS incl. Extra Items (Annual)":"0.58","EPS incl. Extra Items (TTM)":"0.56","Free Cash Flow (Per Share TTM)":"0.19","Dividend (Per Share 5Y)":"0.08"},"Valuation":{"P/E excl. Extra Items (Annual)":"56.76","P/E excl. Extra Items (TTM)":"58.92","P/E Normalized (Annual)":"64.49","Price to sales (Annual)":"2.04","Price to sales (TTM)":"2.11","Price to Tangible Book (Annual)":"12.78","Price to Tangible Book (Quarterly)":"12.95","Price to Free Cash Flow (Per Share Annual)":"175.36","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"172.43","Price to Book (Annual)":"4.39","Price to Book (Quarterly)":"4.40","P/E Basic excl. Extra Items (TTM)":"24.34","P/E excl. Extra Items High (TTM)":"43.78","P/E excl. Extra Items Low (TTM)":"8.18","P/E incl. Extra Items (TTM)":"58.92","Net Debt (Interim)":"9,822.84","Net Debt (Annual)":"12,270.48","Dividend Yield (5Y)":"0.50","Dividend Yield":"0.15","Current Dividend Yield (TTM)":"0.15"},"Financial Strength":{"Free Cash Flow (Annual)":"254.13","Current Ratio (Annual)":"1.09","Net Interest coverage (Annual)":"3.37","Long Term Debt/Equity (Annual)":"40.12","Payout Ratio (Annual)":"8.54","Quick Ratio (Annual)":"0.88","Total Debt/Total Equity (Annual)":"160.58","Current EV/Free Cash Flow (Annual)":"417.26","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.07","Long Term Debt/Equity (Quarterly)":"44.66","Quick Ratio (Quarterly)":"0.85","Total Debt/Total Equity (Quarterly)":"149.37","Free Cash Flow (TTM)":"258.45","Net Interest Coverage (TTM)":"4.45","Payout Ratio (TTM)":"8.78"},"Margins":{"Gross Margin (Annual)":"39.52","Gross Margin (TTM)":"39.42","Net Profit Margin % (Annual)":"6.20","Net Profit Margin (TTM)":"6.14","Operating Margin (Annual)":"8.41","Operating Margin (TTM)":"8.49","Pretax Margin (TTM)":"8.11","Pretax Margin (Annual)":"8.16","Operating Margin (5Y)":"7.18","Pretax Margin (5Y)":"7.26","Free Operating Cash Flow/Revenue (5Y)":"-7.60","Free Operating Cash Flow/Revenue (TTM)":"1.22","Gross Margin (5Y)":"38.48","Net Profit Margin (5Y)":"4.65"},"Management Effectiveness":{"Return on Assets (Annual)":"3.84","Return on Equity (TTM)":"3.50","Return on Average Equity (Annual)":"7.47","Return on Average equity (TTM)":"7.13","Return on Investment (Annual)":"8.74","Return on Investment (TTM)":"8.17","Return on Average Assets (5Y)":"2.62","Return on Average Equity (5Y)":"3.60","Return on Investment (5Y)":"5.20","Asset Turnover (Annual)":"0.62","Asset Turnover (TTM)":"0.57","Inventory Turnover (Annual)":"3.98","Inventory Turnover (TTM)":"3.54","Net Income/Employee (Annual)":"87,621.77","Net Income/Employee (TTM)":"82,518.54","Receivables Turnover (Annual)":"3.19","Receivables Turnover (TTM)":"2.94","Revenue/Employee (Annual)":"1,413,810.00","Revenue/Employee (TTM)":"1,344,186.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"-13.08","Revenue Growth Rate (5Y)":"25.33","EPS Growth (Quarterly YoY)":"-13.99","EPS Growth (TTM YoY)":"130.88","EPS Growth Rate (5Y)":"6.31","Dividend Growth Rate (3Y)":"-23.11","Revenue Growth (TTM YoY)":"8.53","Revenue Growth (Per Share 5Y)":"19.34","Revenue Growth Rate (3Y)":"20.93","EPS Growth Rate (3Y)":"-2.72","Book Value Growth Rate (Per Share 5Y)":"10.92","Tangible Book Value Total Equity CAGR (5Y)":"2.60","Capital Spending growth rate 5 year":"-2.03","EBITDA CAGR (5Y)":"22.34","EBITDA Interim CAGR (5Y)":"18.48","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"30.05","Net Profit Margin Growth Rate (5Y)":"-7.22"},"Income Statement":{"Revenue (Annual)":"21,806.61","Revenue (TTM)":"21,118.51","EBITD (Annual)":"3,009.35","EBITD (TTM)":"2,373.60","Earnings Before Taxes (Annual)":"1,779.44","Earnings Before Taxes (TTM)":"1,713.27","Net Income to Common (Annual)":"783.73","Net Income to Common (TTM)":"762.61","Earnings Before Taxes Normalized (Annual)":"1,655.71","Net Income Available to Common Normalized (Annual)":"689.76","Diluted Normalized EPS excl. Extra Items (TTM)":"0.59"}}}